Therapeutic Potential of Cannabinoids in Psychosis. Leweke F.M., Mueller J.K., Lange B., Rohleder C. Biological Psychiatry, 2016, 79, (7) 604-612. doi: 10.1016/j.biopsych.2015.11.018. Abstract Over recent years, the interest in the endocannabinoid system (ECS) as a new target for the treatment of schizophrenia has evolved. The ECS represents one of the most relevant neurotransmitter systems in the brain and mainly fulfills a homeostatic role in terms of neurotransmission but also with respect to inflammatory processes. Two main approaches to the modulation of endocannabinoid functioning have been chosen so far. First, the selective blockade or inverse agonism of the type 1 cannabinoid receptor has been tested for [...]
Lire la suiteFamilial abnormalities of endocannabinoid signaling in schizophrenia Dagmar Koethe, Franziska Pahlisch, Martin Hellmich , Cathrin Rohleder , Juliane K. Mueller, Andreas Meyer-Lindenberg , E. Fuller Torrey, Daniele Piomelli and F. Markus Leweke, THE WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2018 https://doi.org/10.1080/15622975.2018.1449966 ABSTRACT Objectives : Epidemiological and experimental evidence suggests that the endocannabinoid system plays a pathophysiological role in schizophrenia. This is reflected by elevated cerebrospinal levels of the endocannabinoid anandamide in schizophrenia and its initial prodromal states. Methods : We analyzed plasma concentrations of anandamide, 2-arachidonoyl-sn-glycerol, palmitoylethanolamide and oleoylethanolamide from 25 twin pairs discordant for schizophrenia, six discordant for bipolar disorder and eight healthy twin pairs to [...]
Lire la suiteMeasuring Disturbance of the Endocannabinoid System in Psychosis. A Systematic Review and Meta-analysis Amedeo Minichino, MD1; Morwenna Senior, MD1; Natascia Brondino, PhD2; et al Sam H Zhang, BA1; Beata R Godwlewska, PhD1; Philip W.J Burnet, PhD1; Andrea Cipriani, PhD1,3; Belinda R. Lennox, DM1 JAMA Psychiatry, Published online June 5, 2019. doi:10.1001/jamapsychiatry.2019.0970 Editorial : Pathophysiology of Endocannabinoid Signaling in Schizophrenia David W. Volk, MD, PhD; David A. Lewis, MD Question Is the endocannabinoid system abnormal in people with psychosis? Findings In this systematic review and meta-analysis of 18 studies, a higher tone of the endocannabinoid system was observed in people with psychosis, a finding that was consistent across all stages of illness and independent of antipsychotic treatment and current cannabis use. This increased tone was [...]
Lire la suiteFluorinated Cannabidiol Derivatives : Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects Aviva Breuer, Christeene G. Haj, Manoela V. Fogaça, Felipe V. Gomes, Nicole, Rodrigues Silva, João Francisco Pedrazzi, Elaine A. Del Bel, Jaime C. Hallak, José, A. Crippa, Antonio W. Zuardi, Raphael Mechoulam, Francisco S. Guimarães PLOS ONE, Research Article, 2016 | DOI:10.1371/journal.pone.0158779 July 14, 2016 Abstract Cannabidiol (CBD) is a major Cannabis sativa constituent, which does not cause the typical marijuana psychoactivity. However, it has been shown to be active in a numerous pharmacological assays, including mice tests for anxiety, obsessive-compulsive disorder, depression and schizophrenia. In human trials [...]
Lire la suitePharmacological properties of cannabidiol in the treatment of psychiatric disorders : a critical overview G. M. Mandolini, M. Lazzaretti, A. Pigoni, L. Oldani, G. Delvecchio and P. Brambilla Epidemiology and Psychiatric Sciences, 2018, 27, 327–335. © Cambridge University Press 2018 doi : 10.1017/S2045796018000239 Abstract : Cannabidiol (CBD) represents a new promising drug due to a wide spectrum of pharmacological actions. In order to relate CBD clinical efficacy to its pharmacological mechanisms of action, we performed a bibliographic search on PUBMED about all clinical studies investigating the use of CBD as a treatment of psychiatric symptoms. Findings to date suggest that (a) CBD may exert antipsychotic [...]
Lire la suiteCannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment Amir Englund, Paul D Morrison, Judith Nottage, Dominic Hague, Fergus Kane1, Stefania Bonaccorso1, James M Stone, Avi Reichenberg, Rudolf Brenneisen, David Holt, Amanda Feilding, Lucy Walker, Robin M Murray and Shitij Kapur Journal of Psychopharmacology, 2012 Doi : 10.1177/0269881112460109 Abstract Community-based studies suggest that cannabis products that are high in Δ9-tetrahydrocannabinol (THC) but low in cannabidiol (CBD) are particularly hazardous for mental health. Laboratory-based studies are ideal for clarifying this issue because THC and CBD can be administered in pure form, under controlled conditions. In a between-subjects design, we tested the hypothesis that pre-treatment with CBD inhibited [...]
Lire la suiteCannabidiol, a Cannabis sativa constituent, as an antipsychotic drug A.W. Zuardi, J.A.S. Crippa, J.E.C. Hallak, F.A. Moreira and F.S. Guimarães Brazilian Journal of Medical and Biological Research, 2006, 39, 421-429 ISSN 0100-879X Review Abstract A high dose of Δ9-tetrahydrocannabinol, the main Cannabis sativa (cannabis) component, induces anxiety and psychotic-like symptoms in healthy volunteers. These effects of Δ9-tetrahydrocannabinol are significantly reduced by cannabidiol (CBD), a cannabis constituent which is devoid of the typical effects of the plant. This observation led us to suspect that CBD could have anxiolytic and/or antipsychotic actions. Studies in animal models and in healthy volunteers clearly suggest an anxiolytic-like effect of CBD. The [...]
Lire la suiteIndividual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function Celia J. A. Morgan, Tom P. Freeman, Chandni Hindocha, Grainne Schafer, Chelsea Gardner and H. Valerie Curran Translational Psychiatry, 2018, 8, 181 DOI 10.1038/s41398-018-0191-x https://www.researchgate.net/publication/264860201 Abstract The main active ingredient in cannabis, delta-9-tetrahydrocannabinol (THC), can acutely induce psychotic symptoms and impair episodic and working memory. Another major constituent, cannabidiol (CBD), may attenuate these effects. This study aimed to determine the effects of THC and CBD, both alone and in combination on psychotic symptoms and memory function. A randomised, double-blind crossover design compared the effects of (i) placebo, (ii) THC 8mg, (iii) CBD [...]
Lire la suiteCannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment Englund A, Morrison PD, Nottage J, Hague D, Kane F, Bonaccorso S, Stone JM, Reichenberg A, Brenneisen R, Holt D, Feilding A, Walker L, Murray RM, Kapur S. Beckley Foundation, 2017. https://beckleyfoundation.org/resource/cannabidiol-inhibits-thc-elicited-paranoid-symptoms-and-hippocampal-dependent-memory-impairment/ Abstract Community-based studies suggest that cannabis products that are high in delta9-tetrahydrocannabinol (THC) but low in cannabidiol (CBD) are particularly hazardous for mental health. Laboratory-based studies are ideal for clarifying this issue because THC and CBD can be administered in pure form, under controlled conditions. In a between-subjects design, we tested the hypothesis that pre-treatment with CBD inhibited THC-elicited psychosis and cognitive impairment. Healthy participants were [...]
Lire la suiteCannabis use and mental health: risks and benefits Wayne HALL, · Eva HOCH, · Valentina LORENZETTI European Archives of Psychiatry and Clinical Neuroscience, february 2019 https://doi.org/10.1007/s00406-019-00986-2 © Springer-Verlag GmbH Germany, part of Springer Nature 2019 In public debates about cannabis policy, two competing claims are often made about how cannabis use may affect mental health. One is that cannabis use by young adults and vulnerable individuals across the lifespan can be a contributory cause of : a cannabis dependence syndrome; schizophreniform psychoses; anxiety and depressive disorders; acute and perhaps chronic cognitive impairment, and structural and functional changes in brain pathways implicated in reward, learning and [...]
Lire la suite